

Yeung-Chul Mun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296920/publications.pdf>

Version: 2024-02-01

119
papers

1,126
citations

394421

19
h-index

454955

30
g-index

121
all docs

121
docs citations

121
times ranked

2214
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study. <i>Osteoporosis International</i> , 2022, 33, 367-377.	3.1	5
2	Suppressive effect of Î±-mangostin for cancer stem cells in colorectal cancer via the Notch pathway. <i>BMC Cancer</i> , 2022, 22, 341.	2.6	8
3	Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. <i>Blood Research</i> , 2022, 57, 20-28.	1.3	10
4	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 4969-4977.	2.2	1
5	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
6	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
7	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	5
8	Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT. <i>Blood</i> , 2021, 138, 3757-3757.	1.4	0
9	Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 2889-2889.	1.4	0
10	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
11	Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia. <i>Hematology</i> , 2021, 26, 904-913.	1.5	4
12	Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). <i>British Journal of Haematology</i> , 2020, 189, 303-312.	2.5	21
13	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. <i>Annals of Hematology</i> , 2020, 99, 1283-1291.	1.8	8
14	Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species. <i>Molecules and Cells</i> , 2020, 43, 813-820.	2.6	3
15	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Yonsei Medical Journal</i> , 2020, 61, 452.	2.2	2
16	Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCR. <i>Laboratory Medicine Online</i> , 2020, 10, 321-325.	0.2	0
17	Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study. <i>Blood</i> , 2020, 136, 51-52.	1.4	1
18	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 656-664.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. <i>Annals of Hematology</i> , 2019, 98, 2273-2281.	1.8	2
20	Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional Dyspepsia. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 212-221.	2.4	24
21	Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS). <i>Blood</i> , 2019, 134, 1643-1643.	1.4	2
22	Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). <i>Blood</i> , 2019, 134, 3114-3114.	1.4	0
23	Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study. <i>Blood</i> , 2019, 134, 4035-4035.	1.4	0
24	Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2018, 97, 955-965.	1.8	3
25	Anaplastic Large Cell Lymphoma with Massive Eosinophilia and Complex Karyotype Initially Misdiagnosed as Chronic Eosinophilic Leukemia. <i>Laboratory Medicine Online</i> , 2018, 8, 56.	0.2	0
26	Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). <i>Journal of Korean Medical Science</i> , 2018, 33, e142.	2.5	5
27	Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2018, 38, 160-164.	2.5	1
28	GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. <i>Annals of Laboratory Medicine</i> , 2018, 38, 296-305.	2.5	3
29	The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study. <i>Blood</i> , 2018, 132, 4853-4853.	1.4	1
30	Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study. <i>Blood</i> , 2018, 132, 4252-4252.	1.4	7
31	Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. <i>Laboratory Medicine Online</i> , 2018, 8, 41.	0.2	0
32	Inhibition of Autophagy with 3-Methyladenine Potentiates Bortezomib-Induced Apoptosis of Myeloma Cell Via up Regulation of Mitochondrial Reactive Oxygen Species. <i>Blood</i> , 2018, 132, 4472-4472.	1.4	0
33	Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2018, 132, 3017-3017.	1.4	0
34	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. <i>Blood</i> , 2018, 132, 3876-3876.	1.4	0
35	Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up. <i>Blood</i> , 2018, 132, 1733-1733.	1.4	0
36	Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S16.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 7180-7188.	7.0	57
38	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
39	Characteristics of Chromosome 17p Aberrations Identified by Metaphase Cytogenetics, Interphase FISH and Sequencing in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e37.	0.4	0
40	Management of immune thrombocytopenia: Korean experts recommendation in 2017. <i>Blood Research</i> , 2017, 52, 254.	1.3	20
41	Neutrophilic Leukemoid Reaction Associated with Malignancy Initially Suspected as Chronic Neutrophilic Leukemia. <i>Laboratory Medicine Online</i> , 2017, 7, 206.	0.2	0
42	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
43	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
44	Lymphedema Associated With Primary Amyloidosis: A Case Study. <i>Annals of Rehabilitation Medicine</i> , 2017, 41, 887.	1.6	0
45	Two Cases of Medical Device-Related <i>Corynebacterium striatum</i> Infection: A Meningitis and A Sepsis. <i>Annals of Clinical Microbiology</i> , 2016, 19, 28.	0.1	1
46	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2016, 11, e0166245.	2.5	6
47	Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. <i>Haematologica</i> , 2016, 101, 717-723.	3.5	129
48	Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. <i>Annals of Hematology</i> , 2016, 95, 337-344.	1.8	22
49	Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 341-347.	1.3	30
50	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
51	Prognostic Impact of Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5432-5432.	1.4	0
52	Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation. <i>Blood</i> , 2016, 128, 3375-3375.	1.4	0
53	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
54	Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study. <i>Blood</i> , 2016, 128, 1920-1920.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL). <i>Blood</i> , 2016, 128, 3466-3466.	1.4	0
56	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5683-5683.	1.4	0
57	Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH Rearrangements. <i>Annals of Laboratory Medicine</i> , 2015, 35, 128-131.	2.5	6
58	Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia. <i>Cancer Genetics</i> , 2015, 208, 630-635.	0.4	5
59	Weekly rituximab consolidation following four cycles of CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
60	Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. <i>Journal of Clinical Virology</i> , 2015, 73, 64-69.	3.1	25
61	Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial. <i>Blood</i> , 2015, 126, 476-476.	1.4	9
62	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 44985-44994.	1.8	17
63	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
64	Therapeutic Plasma Exchange for a Patient with Severe Cold Agglutinin Disease. <i>The Korean Journal of Blood Transfusion</i> , 2015, 26, 75-80.	0.4	0
65	Manipulation of β -catenin pathway to overcome endocrine resistance in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11530-e11530.	1.6	0
66	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 675-683.	1.7	2
67	Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib. <i>Blood</i> , 2015, 126, 4053-4053.	1.4	0
68	Abstract B49: Inhibition of β -catenin pathway to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. , 2015, , .		0
69	Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines. <i>Journal of Korean Medical Science</i> , 2014, 29, 164.	2.5	55
70	Transplant physicians' perceptions of cord blood transplantation in Korea: a questionnaire survey. <i>Blood Research</i> , 2014, 49, 228.	1.3	2
71	Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 445.	1.7	24
72	ETV6/RUNX1 Rearrangement Identified by RT-PCR without Evidence on FISH. <i>Acta Haematologica</i> , 2014, 132, 122-124.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , 2014, 93, 1353-1361.	1.8	18
74	Topoisomerase II Alpha and Microtubule-associated Protein-tau as a Predictive Marker in Axillary Lymph Node Positive Breast Cancer. <i>Tumori</i> , 2014, 100, 80-86.	1.1	5
75	Chromothripsis Identified by Copy Number Profiling in a Case of Plasma Cell Leukaemia. <i>Journal of Laboratory Medicine and Quality Assurance</i> , 2014, 36, 107-112.	0.4	0
76	Systemic Epstein-Barr Virus-Positive T-cell Lymphoproliferative Disease of Childhood Presenting as Hemophagocytic Lymphohistiocytosis with Chromosomal Abnormalities. <i>Journal of Laboratory Medicine and Quality Assurance</i> , 2014, 36, 210-215.	0.4	0
77	Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. <i>Annals of Hematology</i> , 2013, 92, 459-469.	1.8	19
78	Clinical features and treatment outcome of primary systemic light chain amyloidosis in Korea: Results of multicenter analysis. <i>American Journal of Hematology</i> , 2013, 88, 52-55.	4.1	14
79	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2013, 161, 339-347.	2.5	72
80	Single Nucleotide Polymorphism Array-Based Karyotyping in Acute Myeloid Leukemia or Myelodysplastic Syndrome with Trisomy 8 as the Sole Chromosomal Abnormality. <i>Acta Haematologica</i> , 2013, 129, 154-158.	1.4	5
81	Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. <i>British Journal of Haematology</i> , 2013, 163, 62-71.	2.5	6
82	A proposal for improvement in the utilization rate of banked cord blood. <i>Blood Research</i> , 2013, 48, 5.	1.3	8
83	Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. <i>Blood</i> , 2013, 122, 5379-5379.	1.4	0
84	A genome-wide single-nucleotide polymorphism array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 961-968.	4.1	8
85	Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2012, 96, 327-333.	1.6	8
86	Sole Trisomy 22 Not Associated with inv(16) in Myelodysplastic Syndrome. <i>The Ewha Medical Journal</i> , 2012, 35, 62.	0.2	0
87	Additional Genomic Aberrations Identified by Single Nucleotide Polymorphism Array-Based Karyotyping in an Acute Myeloid Leukemia Case with Isolated del(20q) Abnormality. <i>Annals of Laboratory Medicine</i> , 2012, 32, 445-449.	2.5	4
88	Ring Chromosome 5 in Acute Myeloid Leukemia Defined by Whole-genome Single Nucleotide Polymorphism Array. <i>Annals of Laboratory Medicine</i> , 2012, 32, 307-311.	2.5	3
89	<i>VEGFA</i> and <i>VEGFR2</i> genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. <i>Cancer Science</i> , 2012, 103, 497-503.	3.9	33
90	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. <i>Blood</i> , 2012, 120, 2683-2683.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Array-Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype. <i>Journal of Clinical Oncology</i> , 2011, 29, 4702-4708.	1.6	30
92	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. <i>Blood</i> , 2011, 118, 1517-1517.	1.4	6
93	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1990-1990.	1.4	0
94	Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach. <i>The Korean Journal of Hematology</i> , 2010, 45, 171.	0.7	15
95	VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2010, 116, 994-994.	1.4	0
96	Acute Fibrinous and Organizing Pneumonia Following Hematopoietic Stem Cell Transplantation. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 156.	1.7	43
97	Prognostic Significance of CD44s Expression in Biliary Tract Cancers. <i>Annals of Surgical Oncology</i> , 2008, 15, 1155-1160.	1.5	12
98	Effects of Transmigration of Bone Marrow Nuclear Cells Through Endothelial Cell and Stromal Cell by Leukotriene B4 and Inhibition of Reactive Oxygen Species. <i>Ewha Medical Journal</i> , 2008, 31, 65.	0.0	0
99	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. <i>Blood</i> , 2008, 112, 5184-5184.	1.4	1
100	Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia. <i>Acta Haematologica</i> , 2007, 118, 205-208.	1.4	37
101	The Results of Danazol Therapy in Patients with Chronic Immune Thrombocytopenic Purpura Who Failed with Corticosteroid Therapy. <i>The Korean Journal of Hematology</i> , 2007, 42, 353.	0.7	1
102	Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 1-5.	4.1	51
103	Vascular Complications in Patients with Essential Thrombocythemia. <i>The Korean Journal of Hematology</i> , 2006, 41, 149.	0.7	0
104	The LTB4 Receptor Is Involved Not Only in the Downstream Pathway of rh-G-CSF Mobilization but in the LTB4 Mobilization Pathway in C57BL/6 Mice. <i>Blood</i> , 2006, 108, 5216-5216.	1.4	0
105	The Intention To Treat Analysis of the Different Post Remission Therapy Modalities in AML Patients with the Intermediate Risk Group (IPG)-Based on Cytogenetics. <i>Blood</i> , 2006, 108, 4563-4563.	1.4	0
106	Augmented Effects on Neovascularization by Mixing the Conditioned Medium from Early EPCs into Late EPCs Derived from Human Cord Blood. <i>Blood</i> , 2006, 108, 3936-3936.	1.4	0
107	A Case of Coexistent Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>The Korean Journal of Hematology</i> , 2005, 40, 41.	0.7	2
108	Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2005, 37, 370.	3.0	4

#	ARTICLE	IF	CITATIONS
109	Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. <i>Experimental and Molecular Medicine</i> , 2005, 37, 45-50.	7.7	29
110	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3288-3288.	1.4	0
111	Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study. <i>Cancer Research and Treatment</i> , 2003, 35, 213-217.	3.0	0
112	Effect of Neutrophil Elastase inhibitor, ICI 200,355, on Interleukin-1 Induced acute lung injury in rats. <i>Yeungnam University Journal of Medicine</i> , 2002, 19, 55.	0.1	0
113	The Influence of Fat-Free Mass to Maximum Exercise Performance in Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2002, 52, 346.	0.2	1
114	The Differences of the Smoking Habit Between Emphysema and Chronic Bronchitis. <i>Tuberculosis and Respiratory Diseases</i> , 2001, 50, 693.	0.2	0
115	The Differences in Resting Pulmonary Function in Relation to the Nutritional status of Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2001, 51, 570.	0.2	2
116	Relative Risk for Lung Cancer According to Smoking Habits in Korean. <i>Tuberculosis and Respiratory Diseases</i> , 2000, 48, 331.	0.2	1
117	A Case of Combined Small Cell Carcinoma with Non-Small Cell Lung Carcinoma, Adenocarcinoma and Squamous Cell Carcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2000, 48, 72.	0.2	0
118	Diagnostic Value of Cyfra 21-1 in Differential Diagnosis of Pleural Effusion. <i>Tuberculosis and Respiratory Diseases</i> , 1999, 47, 50.	0.2	0
119	Gene expression profile related to prognosis of acute myeloid leukemia. <i>Oncology Reports</i> , 0, , .	2.6	8